BioMarin delays refiling approval request for hemophilia gene therapy
The once-and-done gene therapy, initially rejected by the FDA in summer 2020, could potentially provide a genetic fix for a bleeding disorder that today can require multiple prophylactic injections a week. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 31, 2022 Category: Health Management Authors: Ron Leuty Source Type: news
' It's an Amazing Time to Be a Hemophilia Provider'' It's an Amazing Time to Be a Hemophilia Provider '
New drugs such as emicizumab (Hemlibra) are transforming the lives of patients with hemophilia A, and more are on their way."It ' s an amazing time to be a hemophilia provider," says Alice D. Ma, MD.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Tanzania: Govt Unveils Hemophilia Clinic At BMH
[Daily News] THE government has unveiled a hemophilia clinic at the Benjamin Mkapa Hospital (BMH) in a bid to bring closer medication to people with the rare diseases in Central Zone and neighbouring regions. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 26, 2022 Category: African Health Source Type: news
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Anew analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for patients, which could result in as much as $730,000 in savings to the health care system and increase a patient ’s income by as much as $9,500 in the year following treatment. (Source: The Catalyst)
Source: The Catalyst - May 18, 2022 Category: Pharmaceuticals Authors: Katie Koziara Tags: Medicines in Development Personalized Medicine Source Type: news
Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
Roche (SIX: RO, ROG; OTCQX: RHHBY) has extended its commitment to the World Federation of Hemophilia (WFH) Humanitarian Aid Program until the end of 2028. Roche’s prophylactic treatment will be provided to the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with haemophilia A in locations where there is little to no access to treatment. (Source: World Pharma News)
Source: World Pharma News - May 12, 2022 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people withhaemophilia A in locations where there is little to no access tohaemophilia treatmentProphylactic treatment aims to prevent bleeds and allow people withhaemophilia to achieve quality of life comparable to non-haemophilic individuals. Access to this is particularly restricted in developing countries, with the limited healthcare resources reserved for emergency situations and acute bleedsMore than 940 people across 30 countries have already benefited from Roche ’s donations since the start of the partnership i...
Source: Roche Media News - May 10, 2022 Category: Pharmaceuticals Source Type: news
Gambia: Gambia Observes World Haemophilia Day
[The Point] In a bid to create more awareness through community outreach programmes on Haemophilia, Safe Motherhood and Haemophilia Foundation recently organised a day's sensitisation forum in observance of World Haemophilia Day. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 26, 2022 Category: African Health Source Type: news
Tanzania: Haemophilia Society Calls Govt to Set Budget for Treatment
[Daily News] THE Haemophilia Society of Tanzania (HST) is calling upon the government to begin setting a budget for the purchase of treatment products for patients with haemophilia and other blood diseases. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 25, 2022 Category: African Health Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Basel, 25 April 2022Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early...
Source: Roche Media News - April 25, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news
‘Time is blood’: Researchers devise shortcut to AHA diagnosis ‘Time is blood’: Researchers devise shortcut to AHA diagnosis
Researchers have developed an algorithm to help clinicians determine whether patients have acquired hemophilia A (AHA), a rare bleeding disorder that mainly affects elderly men with medical problems.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 20, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Valoctocogene Roxaparvovec Evaluated in Severe Hemophilia A
In open - label study, substantial increase seen in factor VIII activity at weeks 49 to 52 of follow - up (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 18, 2022 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news
Valoctocogene Roxaparvovec Evaluated in Severe Hemophilia A
FRIDAY, March 18, 2022 -- For men with severe hemophilia A, treatment with valoctocogene roxaparvovec, an adeno-associated virus 5-based gene-therapy vector, yields a significant increase in factor VIII activity, with a reduction in treated bleeding... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 18, 2022 Category: Pharmaceuticals Source Type: news
Gene Therapy for Hemophilia A'Transforming and Liberating'Gene Therapy for Hemophilia A'Transforming and Liberating '
One year after infusion of a gene-transfer product, patients with the bleeding disorder had significant improvements in clotting factor production and dramatic reductions in factor concentrate use.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 16, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More Exercise for People With Hemophilia, Experts Advise More Exercise for People With Hemophilia, Experts Advise
Regular physical activity can increase joint stability and function, reduce the risk of injury, and improve quality of life in people with hemophilia, concludes a consensus group.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 25, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
